This Indian study demonstrated telmisartan to be efficacious and tolerable for BP control in Indian hypertension patients when used as monotherapy or in combination therapy. The benefits of telmisartan were independent of age, duration, and stages of hypertension.

Dry eye prevalence was significantly higher among type 2 diabetics with nephropathy (T2DN) compared to those without renal complications (55.6% vs. 37.3%). Factors such as advanced age, elevated HbA1C levels & reduced eGFR were independently associated with DE in T2DN patients. T2DN patients with DE showed higher rates of comorbidities, along with elevated plasma glucose, HbA1C, urea, creatinine, and CRP-hs levels.

Children diagnosed with hypertension faced a daunting 2.1-fold increase in the risk of major adverse cardiac events later in life (HR: 2.1). Additionally, they also had a higher risk of stroke (HR, 2.7), hospitalization for MI or unstable angina (HR, 1.8), coronary intervention (HR, 4.1) & congestive heart failure (HR, 2.6) compared to non-hypertensive counterparts. There was no difference in CVD death risk (HR 1.0).